Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Prostate Cancer

Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases
A Randomized Double-Blind, Placebo-Controlled Phase III Study of Early Versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men With Prostate Cancer Metastatic to Bone
Status: Enrolling
Updated:  11/23/2015
Riverview Uw Cancer Center
mi
from
Wisconsin Rapids, WI
Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases
A Randomized Double-Blind, Placebo-Controlled Phase III Study of Early Versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men With Prostate Cancer Metastatic to Bone
Status: Enrolling
Updated: 11/23/2015
Riverview Uw Cancer Center
mi
from
Wisconsin Rapids, WI
Click here to add this to my saved trials
Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases
A Randomized Double-Blind, Placebo-Controlled Phase III Study of Early Versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men With Prostate Cancer Metastatic to Bone
Status: Enrolling
Updated:  11/23/2015
Welch Cancer Center at Sheridan Memorial Hospital
mi
from
Sheridan, WY
Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases
A Randomized Double-Blind, Placebo-Controlled Phase III Study of Early Versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men With Prostate Cancer Metastatic to Bone
Status: Enrolling
Updated: 11/23/2015
Welch Cancer Center at Sheridan Memorial Hospital
mi
from
Sheridan, WY
Click here to add this to my saved trials
Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases
A Randomized Double-Blind, Placebo-Controlled Phase III Study of Early Versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men With Prostate Cancer Metastatic to Bone
Status: Enrolling
Updated:  11/23/2015
Cross Cancer Institute at University of Alberta
mi
from
Edmonton,
Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases
A Randomized Double-Blind, Placebo-Controlled Phase III Study of Early Versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men With Prostate Cancer Metastatic to Bone
Status: Enrolling
Updated: 11/23/2015
Cross Cancer Institute at University of Alberta
mi
from
Edmonton,
Click here to add this to my saved trials
A Pilot Study of 123I-MIP-1072 SPECT/CT Imaging With Optional Compact Gamma Camera Probe Imaging in Men With Prostate Cancer Undergoing Prostatectomy
A Phase 1 Pilot Study of 123I-MIP-1072 Single Photon Emission Computed Tomography (SPECT)/CT Imaging With Optional Compact Gamma Camera Probe Imaging in Men With Prostate Cancer Undergoing Prostatectomy
Status: Enrolling
Updated:  11/23/2015
CCR/NCI - Molecular Imaging Program
mi
from
Bethesda, MD
A Pilot Study of 123I-MIP-1072 SPECT/CT Imaging With Optional Compact Gamma Camera Probe Imaging in Men With Prostate Cancer Undergoing Prostatectomy
A Phase 1 Pilot Study of 123I-MIP-1072 Single Photon Emission Computed Tomography (SPECT)/CT Imaging With Optional Compact Gamma Camera Probe Imaging in Men With Prostate Cancer Undergoing Prostatectomy
Status: Enrolling
Updated: 11/23/2015
CCR/NCI - Molecular Imaging Program
mi
from
Bethesda, MD
Click here to add this to my saved trials
A Study of 99mTc-MIP-1404 and 99mTc-MIP-1405 in Patients With Metastatic Prostate Adenocarcinoma and Healthy Volunteers
A Phase I Study of the PK, Tissue Distribution and Metabolism of Small Molecule Inhibitors of Prostate Specific Membrane Antigen, 99mTc-MIP-1404 and 99mTc-MIP-1405, in Patients With Metastatic Prostate Adenocarcinoma and Healthy Volunteers
Status: Enrolling
Updated:  11/23/2015
New York Presbyterian Hospital: Weill Medical College of Cornell University
mi
from
New York, NY
A Study of 99mTc-MIP-1404 and 99mTc-MIP-1405 in Patients With Metastatic Prostate Adenocarcinoma and Healthy Volunteers
A Phase I Study of the PK, Tissue Distribution and Metabolism of Small Molecule Inhibitors of Prostate Specific Membrane Antigen, 99mTc-MIP-1404 and 99mTc-MIP-1405, in Patients With Metastatic Prostate Adenocarcinoma and Healthy Volunteers
Status: Enrolling
Updated: 11/23/2015
New York Presbyterian Hospital: Weill Medical College of Cornell University
mi
from
New York, NY
Click here to add this to my saved trials
Pilot Study of 99mTc-MIP-1404 SPECT/CT Imaging in Men With Prostate Cancer Undergoing Prostatectomy and/or Pelvic Lymph Node Dissection
A Phase 1 Pilot Study of 99mTc-MIP-1404 Single Photon Emission Computed Tomography (SPECT)/CT Imaging in Men With Prostate Cancer Undergoing Prostatectomy and/or Pelvic Lymph Node Dissection (PLND)
Status: Enrolling
Updated:  11/23/2015
Weill-Cornell Medical College
mi
from
New York, NY
Pilot Study of 99mTc-MIP-1404 SPECT/CT Imaging in Men With Prostate Cancer Undergoing Prostatectomy and/or Pelvic Lymph Node Dissection
A Phase 1 Pilot Study of 99mTc-MIP-1404 Single Photon Emission Computed Tomography (SPECT)/CT Imaging in Men With Prostate Cancer Undergoing Prostatectomy and/or Pelvic Lymph Node Dissection (PLND)
Status: Enrolling
Updated: 11/23/2015
Weill-Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
A Phase 1 Pilot Study of 99mTc-MIP-1404 SPECT/CT Imaging to Histology in Men With Prostate Cancer
A Phase 1 Pilot Comparison Study of 99mTc-MIP-1404 Single Photon Emission Computed Tomography (SPECT)/CT Imaging to Histology in Men With Prostate Cancer
Status: Enrolling
Updated:  11/23/2015
University of Texas Health Science Center at Houston
mi
from
Houston, TX
A Phase 1 Pilot Study of 99mTc-MIP-1404 SPECT/CT Imaging to Histology in Men With Prostate Cancer
A Phase 1 Pilot Comparison Study of 99mTc-MIP-1404 Single Photon Emission Computed Tomography (SPECT)/CT Imaging to Histology in Men With Prostate Cancer
Status: Enrolling
Updated: 11/23/2015
University of Texas Health Science Center at Houston
mi
from
Houston, TX
Click here to add this to my saved trials
99mTc-MIP-1404 for Imaging Prostate Cancer: Phase I Clinical Study to Assess the Image Quality of a Simplified Kit Formulation Compared to a Multi-step Preparation of 99mTc-MIP-1404
99mTc-MIP-1404 for Imaging Prostate Cancer: Phase I Clinical Study to Assess the Image Quality of a Simplified Kit Formulation Compared to a Multi-step Preparation of 99mTc-MIP-1404
Status: Enrolling
Updated:  11/23/2015
New York Presbyterian Hospital-Weill Cornell Medical College
mi
from
New York, NY
99mTc-MIP-1404 for Imaging Prostate Cancer: Phase I Clinical Study to Assess the Image Quality of a Simplified Kit Formulation Compared to a Multi-step Preparation of 99mTc-MIP-1404
99mTc-MIP-1404 for Imaging Prostate Cancer: Phase I Clinical Study to Assess the Image Quality of a Simplified Kit Formulation Compared to a Multi-step Preparation of 99mTc-MIP-1404
Status: Enrolling
Updated: 11/23/2015
New York Presbyterian Hospital-Weill Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
mi
from
Birmingham, AL
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
mi
from
San Diego, CA
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
mi
from
Denver, CO
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
mi
from
Denver, CO
Click here to add this to my saved trials
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
mi
from
Bradenton, FL
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
mi
from
Bradenton, FL
Click here to add this to my saved trials
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
mi
from
Daytona Beach, FL
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
mi
from
Daytona Beach, FL
Click here to add this to my saved trials
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
mi
from
Fort Lauderdale, FL
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
mi
from
Fort Myers, FL
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
mi
from
Plantation, FL
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
mi
from
Plantation, FL
Click here to add this to my saved trials
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
mi
from
Jeffersonville, IN
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
mi
from
Jeffersonville, IN
Click here to add this to my saved trials
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
mi
from
Wichita, KA
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
mi
from
Wichita, KA
Click here to add this to my saved trials
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
mi
from
Shreveport, LA
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
mi
from
Shreveport, LA
Click here to add this to my saved trials
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
mi
from
Omaha, NE
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
mi
from
Omaha, NE
Click here to add this to my saved trials
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
mi
from
Syracuse, NY
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
mi
from
Syracuse, NY
Click here to add this to my saved trials
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
mi
from
Columbus, OH
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
mi
from
Eugene, OR
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
mi
from
Eugene, OR
Click here to add this to my saved trials
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
mi
from
Myrtle Beach, SC
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
mi
from
Myrtle Beach, SC
Click here to add this to my saved trials
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
mi
from
Dallas, TX
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
mi
from
San Antonio, TX
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
mi
from
Virginia Beach, VA
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
mi
from
Virginia Beach, VA
Click here to add this to my saved trials
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated:  11/30/2015
mi
from
Brighton,
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)
Status: Enrolling
Updated: 11/30/2015
mi
from
Brighton,
Click here to add this to my saved trials
Physical Activity Intervention in African American Men After Radical Prostatectomy
A Pilot Study of Physical Activity Intervention in African American Men After Radical Prostatectomy
Status: Enrolling
Updated:  12/1/2015
Washington University School of Medicine
mi
from
Saint Louis, MO
Physical Activity Intervention in African American Men After Radical Prostatectomy
A Pilot Study of Physical Activity Intervention in African American Men After Radical Prostatectomy
Status: Enrolling
Updated: 12/1/2015
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Toremifene Followed by Radical Prostatectomy in Treating Patients With Stage I or Stage II Prostate Cancer
A Phase II Randomized Controlled Clinical Trial Of The Antiestrogen GTx-006 In Subjects With Prostate Cancer
Status: Enrolling
Updated:  12/1/2015
Hillman Cancer Center at University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Toremifene Followed by Radical Prostatectomy in Treating Patients With Stage I or Stage II Prostate Cancer
A Phase II Randomized Controlled Clinical Trial Of The Antiestrogen GTx-006 In Subjects With Prostate Cancer
Status: Enrolling
Updated: 12/1/2015
Hillman Cancer Center at University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors
Phase I Dose Escalation Trial of Biweekly Alimta (With Vitamin Supplementation) in Combination With Taxotere in Advanced Solid Tumor Patients
Status: Enrolling
Updated:  12/2/2015
Arizona Cancer Center at University of Arizona Health Sciences Center
mi
from
Tucson, AZ
Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors
Phase I Dose Escalation Trial of Biweekly Alimta (With Vitamin Supplementation) in Combination With Taxotere in Advanced Solid Tumor Patients
Status: Enrolling
Updated: 12/2/2015
Arizona Cancer Center at University of Arizona Health Sciences Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Using Walk With Ease Walking Program With Men 65 and Older Being Treated for Prostate Cancer
Feasibility of an Evidence-based Walking Program in a Sample of Men Age >65 Undergoing Treatment for Prostate Cancer
Status: Enrolling
Updated:  12/2/2015
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Using Walk With Ease Walking Program With Men 65 and Older Being Treated for Prostate Cancer
Feasibility of an Evidence-based Walking Program in a Sample of Men Age >65 Undergoing Treatment for Prostate Cancer
Status: Enrolling
Updated: 12/2/2015
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Lycopene or Omega-3 Fatty Acid Nutritional Supplements in Treating Patients With Stage I or Stage II Prostate Cancer
The Molecular Effects of Nutrition Supplements (MENS) Prostate Study
Status: Enrolling
Updated:  12/2/2015
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Lycopene or Omega-3 Fatty Acid Nutritional Supplements in Treating Patients With Stage I or Stage II Prostate Cancer
The Molecular Effects of Nutrition Supplements (MENS) Prostate Study
Status: Enrolling
Updated: 12/2/2015
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Diindolylmethane in Treating Patients Undergoing Surgery for Stage I or Stage II Prostate Cancer
Phase Ib Placebo-Controlled Trial of Diindolylmethane (BR-DIM) in the Study of the Modulation of Intermediate Endpoint Markers in Patients With Prostate Cancer Who Are Undergoing Prostatectomy
Status: Enrolling
Updated:  12/3/2015
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Diindolylmethane in Treating Patients Undergoing Surgery for Stage I or Stage II Prostate Cancer
Phase Ib Placebo-Controlled Trial of Diindolylmethane (BR-DIM) in the Study of the Modulation of Intermediate Endpoint Markers in Patients With Prostate Cancer Who Are Undergoing Prostatectomy
Status: Enrolling
Updated: 12/3/2015
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Click here to add this to my saved trials
Atkins Diet and Prostate Cancer Clinical Trial
Randomized Controlled Clinical Trial of Carbohydrate Restriction Among Men Initiating Androgen Deprivation Therapy For Prostate Cancer
Status: Enrolling
Updated:  12/4/2015
Greater Los Angeles VA Medical Center
mi
from
Los Angeles, CA
Atkins Diet and Prostate Cancer Clinical Trial
Randomized Controlled Clinical Trial of Carbohydrate Restriction Among Men Initiating Androgen Deprivation Therapy For Prostate Cancer
Status: Enrolling
Updated: 12/4/2015
Greater Los Angeles VA Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Atkins Diet and Prostate Cancer Clinical Trial
Randomized Controlled Clinical Trial of Carbohydrate Restriction Among Men Initiating Androgen Deprivation Therapy For Prostate Cancer
Status: Enrolling
Updated:  12/4/2015
University of California at Los Angeles
mi
from
Los Angeles, CA
Atkins Diet and Prostate Cancer Clinical Trial
Randomized Controlled Clinical Trial of Carbohydrate Restriction Among Men Initiating Androgen Deprivation Therapy For Prostate Cancer
Status: Enrolling
Updated: 12/4/2015
University of California at Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Atkins Diet and Prostate Cancer Clinical Trial
Randomized Controlled Clinical Trial of Carbohydrate Restriction Among Men Initiating Androgen Deprivation Therapy For Prostate Cancer
Status: Enrolling
Updated:  12/4/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Atkins Diet and Prostate Cancer Clinical Trial
Randomized Controlled Clinical Trial of Carbohydrate Restriction Among Men Initiating Androgen Deprivation Therapy For Prostate Cancer
Status: Enrolling
Updated: 12/4/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Use of Multiphoton Microscopy in the Diagnosis of Cancer
Use of Multiphoton Microscopy in the Diagnosis of Cancer
Status: Enrolling
Updated:  12/8/2015
Weill-Cornell Medical College
mi
from
New York, NY
Use of Multiphoton Microscopy in the Diagnosis of Cancer
Use of Multiphoton Microscopy in the Diagnosis of Cancer
Status: Enrolling
Updated: 12/8/2015
Weill-Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer
A Multi-institutional Phase I and Biomarker Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer
Status: Enrolling
Updated:  12/8/2015
Georgetown University
mi
from
Washington D.C.,
Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer
A Multi-institutional Phase I and Biomarker Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer
Status: Enrolling
Updated: 12/8/2015
Georgetown University
mi
from
Washington D.C.,
Click here to add this to my saved trials
Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer
A Multi-institutional Phase I and Biomarker Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer
Status: Enrolling
Updated:  12/8/2015
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer
A Multi-institutional Phase I and Biomarker Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer
Status: Enrolling
Updated: 12/8/2015
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Phase I/II Study of Azacitidine, Docetaxel, and Prednisone for Metastatic Prostate Cancer Patients
A Phase I/II Study of Azacitidine (Vidaza), Docetaxel and Prednisone for Patients With Hormone Refractory Metastatic Prostate Cancer Previously Treated With a Taxotere Containing Regimen.
Status: Enrolling
Updated:  12/9/2015
University of Miami, Sylvester Comprehensive Cancer Center
mi
from
Miami, FL
A Phase I/II Study of Azacitidine, Docetaxel, and Prednisone for Metastatic Prostate Cancer Patients
A Phase I/II Study of Azacitidine (Vidaza), Docetaxel and Prednisone for Patients With Hormone Refractory Metastatic Prostate Cancer Previously Treated With a Taxotere Containing Regimen.
Status: Enrolling
Updated: 12/9/2015
University of Miami, Sylvester Comprehensive Cancer Center
mi
from
Miami, FL
Click here to add this to my saved trials
Lenalidomide and Paclitaxel in Prostate Cancer
A Modular Phase I-II Trial of Lenalidomide and Paclitaxel in Men With Castration-Resistant Prostate Cancer and Lymph-Node Dominant Metastases
Status: Enrolling
Updated:  12/10/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Lenalidomide and Paclitaxel in Prostate Cancer
A Modular Phase I-II Trial of Lenalidomide and Paclitaxel in Men With Castration-Resistant Prostate Cancer and Lymph-Node Dominant Metastases
Status: Enrolling
Updated: 12/10/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Leuprolide Acetate or Goserelin Acetate Compared With Observation in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy
Phase II Trial of Temporary Androgen Deprivation Therapy in High Risk Prostate Cancer Following Radical Prostatectomy
Status: Enrolling
Updated:  12/11/2015
The Mayo Clinic
mi
from
Rochester, MN
Leuprolide Acetate or Goserelin Acetate Compared With Observation in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy
Phase II Trial of Temporary Androgen Deprivation Therapy in High Risk Prostate Cancer Following Radical Prostatectomy
Status: Enrolling
Updated: 12/11/2015
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Proton Therapy for High Risk Prostate Cancer
Phase 2/3 Study of Dose-escalated External Beam Radiation Therapy
Status: Enrolling
Updated:  12/14/2015
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Proton Therapy for High Risk Prostate Cancer
Phase 2/3 Study of Dose-escalated External Beam Radiation Therapy
Status: Enrolling
Updated: 12/14/2015
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Functional MRI Use in Prostate Radiation Treatment Planning
A Prospective Study Evaluating Non-Endorectal Coil Functional MRI Identification of Intraprostatic Tumor During Radiation Treatment Planning
Status: Enrolling
Updated:  12/14/2015
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Functional MRI Use in Prostate Radiation Treatment Planning
A Prospective Study Evaluating Non-Endorectal Coil Functional MRI Identification of Intraprostatic Tumor During Radiation Treatment Planning
Status: Enrolling
Updated: 12/14/2015
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostate Cancer
A Phase I Study of Two Different Doses of the Subcutaneous Administration of an Immunotherapeutic Vaccine, DPX-0907 in Advanced Stage Patients With Ovarian, Breast or Prostate Cancer
Status: Enrolling
Updated:  12/14/2015
Rush University Medical Center
mi
from
Chicago, IL
A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostate Cancer
A Phase I Study of Two Different Doses of the Subcutaneous Administration of an Immunotherapeutic Vaccine, DPX-0907 in Advanced Stage Patients With Ovarian, Breast or Prostate Cancer
Status: Enrolling
Updated: 12/14/2015
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostate Cancer
A Phase I Study of Two Different Doses of the Subcutaneous Administration of an Immunotherapeutic Vaccine, DPX-0907 in Advanced Stage Patients With Ovarian, Breast or Prostate Cancer
Status: Enrolling
Updated:  12/14/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostate Cancer
A Phase I Study of Two Different Doses of the Subcutaneous Administration of an Immunotherapeutic Vaccine, DPX-0907 in Advanced Stage Patients With Ovarian, Breast or Prostate Cancer
Status: Enrolling
Updated: 12/14/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostate Cancer
A Phase I Study of Two Different Doses of the Subcutaneous Administration of an Immunotherapeutic Vaccine, DPX-0907 in Advanced Stage Patients With Ovarian, Breast or Prostate Cancer
Status: Enrolling
Updated:  12/14/2015
Duke Univ Med Ctr
mi
from
Durham, NC
A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostate Cancer
A Phase I Study of Two Different Doses of the Subcutaneous Administration of an Immunotherapeutic Vaccine, DPX-0907 in Advanced Stage Patients With Ovarian, Breast or Prostate Cancer
Status: Enrolling
Updated: 12/14/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostate Cancer
A Phase I Study of Two Different Doses of the Subcutaneous Administration of an Immunotherapeutic Vaccine, DPX-0907 in Advanced Stage Patients With Ovarian, Breast or Prostate Cancer
Status: Enrolling
Updated:  12/14/2015
UPMC Cancer Center
mi
from
Pittsburgh, PA
A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostate Cancer
A Phase I Study of Two Different Doses of the Subcutaneous Administration of an Immunotherapeutic Vaccine, DPX-0907 in Advanced Stage Patients With Ovarian, Breast or Prostate Cancer
Status: Enrolling
Updated: 12/14/2015
UPMC Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostate Cancer
A Phase I Study of Two Different Doses of the Subcutaneous Administration of an Immunotherapeutic Vaccine, DPX-0907 in Advanced Stage Patients With Ovarian, Breast or Prostate Cancer
Status: Enrolling
Updated:  12/14/2015
Mary Crowley Cancer Research Center
mi
from
Dallas, TX
A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostate Cancer
A Phase I Study of Two Different Doses of the Subcutaneous Administration of an Immunotherapeutic Vaccine, DPX-0907 in Advanced Stage Patients With Ovarian, Breast or Prostate Cancer
Status: Enrolling
Updated: 12/14/2015
Mary Crowley Cancer Research Center
mi
from
Dallas, TX
Click here to add this to my saved trials